Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suk-Chan Jang

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Safety|November 13, 2020
Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort studyHye-Rim Kang, Suk-Chan Jang, Ju-Young Shin
Lipids in Health and Disease|August 8, 2025
Assessing the impact of aggressive versus intermediate LDL-C goal achievement in Asian adults: a retrospective cohort study using national health insurance service-senior cohortYu-Cheol Lim, Suk-Chan Jang, Eui-Kyung Lee, et al.
Journal of Managed Care & Specialty Pharmacy|May 21, 2026
Health care costs associated with disease progression of untreated chronic hepatitis C in the United StatesSuk-Chan Jang, Ji Haeng Heo, Shao-Hsuan Chang, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 18, 2025
Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort studySuk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, et al.
Transplantation|April 23, 2026
Clinical Impact and Cost-effectiveness of Everolimus Combination Therapy in Liver Transplant Recipients: Focus on the Risk of Cancer, Infection, and Renal FunctionSuk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, et al.
Plos One|October 6, 2025
Lifetime economic burden of hemophilia using a nationwide real-world healthcare dataJoo-Young Byun, Jae-Hoon Jung, Suk-Chan Jang, et al.
Frontiers in Pharmacology|July 5, 2022
Optimal Indicator of Death for Using Real-World Cancer Patients' Data From the Healthcare SystemSuk-Chan Jang, Sun-Hong Kwon, Serim Min, et al.
Cost Effectiveness and Resource Allocation : C/E|June 17, 2026
Exploring trends of cost-effectiveness thresholds in South Korea: systematic review of pharmacoeconomic evaluations since introduction of the positive list systemHyun-Ji Kim, Kyung-Ae Nam, Suk-Chan Jang, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|September 10, 2022
Clinical impact and economic burden of post-transplant infections following heart transplantation: A retrospective nationwide cohort studySuk-Chan Jang, Byeong-Chan Oh, Jin Hyun Nam, et al.
Frontiers in Oncology|February 16, 2024
A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphomaJeong-Yeon Cho, Suk-Chan Jang, Dong-Won Kang, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Safety|November 13, 2020
Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort studyHye-Rim Kang, Suk-Chan Jang, Ju-Young Shin
Lipids in Health and Disease|August 8, 2025
Assessing the impact of aggressive versus intermediate LDL-C goal achievement in Asian adults: a retrospective cohort study using national health insurance service-senior cohortYu-Cheol Lim, Suk-Chan Jang, Eui-Kyung Lee, et al.
Journal of Managed Care & Specialty Pharmacy|May 21, 2026
Health care costs associated with disease progression of untreated chronic hepatitis C in the United StatesSuk-Chan Jang, Ji Haeng Heo, Shao-Hsuan Chang, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 18, 2025
Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort studySuk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, et al.
Transplantation|April 23, 2026
Clinical Impact and Cost-effectiveness of Everolimus Combination Therapy in Liver Transplant Recipients: Focus on the Risk of Cancer, Infection, and Renal FunctionSuk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, et al.
Plos One|October 6, 2025
Lifetime economic burden of hemophilia using a nationwide real-world healthcare dataJoo-Young Byun, Jae-Hoon Jung, Suk-Chan Jang, et al.
Frontiers in Pharmacology|July 5, 2022
Optimal Indicator of Death for Using Real-World Cancer Patients' Data From the Healthcare SystemSuk-Chan Jang, Sun-Hong Kwon, Serim Min, et al.
Cost Effectiveness and Resource Allocation : C/E|June 17, 2026
Exploring trends of cost-effectiveness thresholds in South Korea: systematic review of pharmacoeconomic evaluations since introduction of the positive list systemHyun-Ji Kim, Kyung-Ae Nam, Suk-Chan Jang, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|September 10, 2022
Clinical impact and economic burden of post-transplant infections following heart transplantation: A retrospective nationwide cohort studySuk-Chan Jang, Byeong-Chan Oh, Jin Hyun Nam, et al.
Frontiers in Oncology|February 16, 2024
A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphomaJeong-Yeon Cho, Suk-Chan Jang, Dong-Won Kang, et al.
Pageof 2